Recombivax HB vaccine

BIOLOGICAL2 trials

Sponsors

Merck Sharp & Dohme LLC

Conditions

Bacterial InfectionsVirus Diseases

Phase 3

Safety, Tolerability, and Immunogenicity of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-005)

CompletedNCT01337167

Merck Sharp & Dohme LLCBacterial Infections, Virus Diseases

Start: 2011-04-19End: 2013-05-09Updated: 2018-11-15

A Study of V419 Given Concomitantly With Prevnar 13™ and RotaTeq™ (V419-006)

CompletedNCT01340937

Merck Sharp & Dohme LLCBacterial Infections, Virus Diseases

Start: 2011-05-10End: 2013-07-26Updated: 2018-11-15

Related Papers

Lot-to-lot Consistency, Safety, Tolerability and Immunogenicity of an Investigational Hexavalent Vaccine in US Infants.

2017-02-0116 citations

1112A Phase III Study of the Safety, Tolerability and Immunogenicity of an Investigational Combination Vaccine against Diphtheria, Tetanus, Pertussis (DTaP5), Polio (IPV), Haemophilus influenzae type b (Hib; PRP-OMPC), and Hepatitis B (HepB) in US Infants

Open Forum Infectious Diseases2014-01-01